Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456921 | 1.00 | TSHR (0.57) | TSHRTDP1L3MBTL1MAPK1CYP3A4 | |
| SCHEMBL28837381 | 0.87 | TSHR (0.53) | TSHRL3MBTL1ALDH1A1HSD17B10LMNA | |
| SCHEMBL10731867 | 0.87 | TSHR (0.50) | TSHRTDP1L3MBTL1MAPK1CYP3A4 | |
| SCHEMBL22960674 | 0.86 | TSHR (0.43) | TSHRTDP1L3MBTL1MAPK1CYP3A4 | |
| SCHEMBL23361692 | 0.86 | ALDH1A1 (0.43) | TSHRTDP1L3MBTL1MAPK1CYP3A4 | |
| SCHEMBL6245881 | 0.85 | TSHR (0.57) | TSHRTDP1L3MBTL1MAPK1CYP3A4 | |
| SCHEMBL1830507 | 0.85 | ALDH1A1 (0.43) | TSHRTDP1L3MBTL1MAPK1CYP3A4 | |
| SCHEMBL27636711 | 0.83 | TSHR (0.52) | TSHRTDP1L3MBTL1MAPK1CYP3A4 | |
| SCHEMBL9124986 | 0.83 | ALDH1A1 (0.52) | TSHRTDP1L3MBTL1MAPK1CYP3A4 | |
| SCHEMBL9332290 | 0.82 | TSHR (0.39) | TSHRTDP1L3MBTL1MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 851 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265607-A1 | Treatment Liquid Composition, Set Of Ink Jet Ink Composition And Treatment Liquid Composition, And Treatment Method | SEIKO EPSON CORPORATION (JP) | 2023-08-24 | — | — | US | claimed |
| US-11535979-B2 | Fiber material for cement reinforcement | TEIJIN LIMITED (JP) | 2022-12-27 | — | — | US | claimed |
| US-11382868-B2 | Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same | ICURE PHARMACEUTICAL INC. (KR) | 2022-07-12 | — | — | US | claimed |
| CN-107652222-B | Oxime ester photoinitiators | 巴斯夫欧洲公司 | 2021-09-10 | — | — | CN | claimed |
| US-10919909-B2 | Photoinitiated reactions | LINTFIELD LIMITED (GB) | 2021-02-16 | — | — | US | claimed |
| EP-3248954-B1 | CEMENT OR MORTAR FORMED BODY COMPRISING CEMENT-REINFORCING FIBER MATERIAL | TEIJIN LTD (JP) | 2020-02-19 | — | — | EP | claimed |
| US-20190211031-A1 | PHOTOINITIATED REACTIONS | LINTFIELD LIMITED (GB) | 2019-07-11 | — | — | US | claimed |
| US-20190046463-A1 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME | ICURE PHARMACEUTICAL INC. (KR) | 2019-02-14 | — | — | US | claimed |
| EP-3415141-A1 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME | Icure Pharmaceutical Inc. (KR) | 2018-12-19 | — | — | EP | claimed |
| CN-101802022-B | Photoinitiators for energy curing | LAMBERTI SPA | 2013-03-27 | — | — | CN | claimed |
| EP-2190887-B1 | PHOTOINITIATORS FOR ENERGY CURING | LAMBERTI SPA (IT) | 2011-05-04 | — | — | EP | claimed |
| CN-101802022-A | Photoinitiators for energy curing | LAMBERTI SPA | 2010-08-11 | — | — | CN | claimed |
| US-20100196826-A1 | Photoinitiators for Energy Curing | LAMBERTI SPA (IT) | 2010-08-05 | — | — | US | claimed |
| EP-2190887-A1 | PHOTOINITIATORS FOR ENERGY CURING | Lamberti Spa (IT) | 2010-06-02 | — | — | EP | claimed |
| US-20100093883-A1 | Hydroxamic Esters as Photoinitiators | LAMBERTI SPA (IT) | 2010-04-15 | — | — | US | claimed |
| EP-2121323-A1 | HYDROXAMIC ESTERS AS PHOTOINITIATORS | Lamberti Spa (IT) | 2009-11-25 | — | — | EP | claimed |
| WO-2009037130-A1 | PHOTOINITIATORS FOR ENERGY CURING | LAMBERTI SPA (IT) | 2009-03-26 | — | — | WO | claimed |
| WO-2008104436-A1 | HYDROXAMIC ESTERS AS PHOTOINITIATORS | LAMBERTI SPA (IT) | 2008-09-04 | — | — | WO | claimed |
| US-12637600-B2 | Photocurable composition, cured product of same, photofusible resin composition and adhesive set | RESONAC CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| EP-0152377-A2 | Curable compositions and their use | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637600-B2 | Photocurable composition, cured product of same, photofusible resin composition and adhesive set | ESD, CDH1, ASH2L | TSHR 2827/4885TDP1 2103/4885L3MBTL1 2458/4885 |
| US-10919909-B2 | Photoinitiated reactions | KMO, DECR1, PPOX | TSHR 3231/4885TDP1 440/4885L3MBTL1 3770/4885 |
| US-20100196826-A1 | Photoinitiators for Energy Curing | PPOX, ECPAS, PTGES | TSHR 4756/4885TDP1 1570/4885L3MBTL1 3345/4885 |
| US-20190211031-A1 | PHOTOINITIATED REACTIONS | DOHH, PAH, DBH | TSHR 4176/4885TDP1 549/4885L3MBTL1 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.